// added the section below on July 01 2024 // till here on July 01 2024

Blood Brain Barrier Market

Blood Brain Barrier Market (3rd Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Type of Molecule (Biologics and Small Molecules), Route of Administration (Intravenous and Oral), Target Disease Indication (Amyotrophic Lateral Sclerosis, Leptomeningeal Carcinomatosis, Mucopolysaccharidosis Type II (Hunter Syndrome), Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A) and Multiple Sclerosis) and Therapeutic Area (Lysosomal Storage Disorders, Neurodegenerative Disorders and Neuro-Oncology Disorders) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    375

  • View Count
    22512

The commercial opportunities for BBB penetrating drugs are immense. I believe that if a drug developer has a viable technology and has established the necessary proof-of-concept, there is tremendous potential in terms of revenue generation

- Chief Operating officer, a Canada based Small-sized Company

Blood Brain Barrier Market Size

The blood brain barrier market is estimated to be USD 36 million in 2024 and is projected to reach USD 2,904 million by 2035. The market is anticipated to grow at a CAGR of 49%, during the forecast period 2024-2035.

Blood Brain Barrier Market, By Therapeutics Area

To learn more about this report, request a free sample copy

Blood brain barrier drugs and technologies focus on overcoming the challenges related to the selective nature of blood-brain barrier to deliver therapeutic agents directly to the brain. Over the past few years, increased research and investment activity to understand and overcome the challenges posed by drug developers in the development of blood-brain barrier therapeutics, along with the rising incidences of neurological diseases (such as Alzheimer's and Parkinson's) are driving the demand for therapies that can bypass the blood-brain barrier and is likely to spur innovation and market expansion in this domain. It is worth noting that these innovations include drug delivery systems, nanoparticles, and medical devices that aim to improve treatment efficacy for neurological disorders by enhancing drug transport across the blood-brain barrier.

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer’s disease, brain cancer, multiple sclerosis, Parkinson’s disease and stroke, are characterized by a significant unmet need for effective treatment options. In fact, neurological disorders are the second highest cause of death and the leading cause of disability, worldwide. In 2021, it was reported that nearly 3.4 billion global population suffer from some form of disorder that affects the functioning of the CNS. More than 6 million people are reported to be living with Alzheimer’s, and it is anticipated to increase to nearly 13 million by 2050. Further, it is estimated that nearly one million people in US are affected with Parkinson’s disease, with approximately 90,000 new patients being diagnosed every year in US.

Over time, extensive R&D efforts have resulted in the development of a number of versatile blood-brain barrier technologies. These technologies have been designed either to externally alter the permeability of the blood-brain barrier or augment the blood-brain barrier penetrating capabilities of compatible pharmacological interventions. Owing to these advancements, there has been a marked rise in the number of new entrants in this field and we anticipate significant growth in the coming years.

Currently, blood-brain barrier market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines.

Blood Brain Barrier Market Share Insights

The blood-brain barrier market report presents an in-depth analysis of the various BBB penetrating drugs and non-invasive technologies, across different segments, as defined in the table below:

Blood-Brain Barrier Market: Report Attributes / Market Segmentations

Key Report Attributes

Details

Base Year

2023

Forecast Period

2024-2035

Market Size Value in 2024

USD 36 Million

Growth Rate

CAGR of 49% from 2024 to 2035

Type of Molecule

  • Small Molecules 
  • Biologics

Target Disease Indication

  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis
  • Mucopolysaccharidosis Type II (Hunter Syndrome)
  • Leptomeningeal Carcinomatosis
  • Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)

Route of Administration

  • Oral
  • Intravenous

Therapeutic Area

  • Neurodegenerative Disorders
  • Lysosomal Storage Disorders 
  • Neuro-Oncology Disorders

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World

Leading Market Players

  • ICBI
  • Denali Therapeutics 
  • JCR Pharmaceuticals
  • Cyclenium Pharma
  • Lauren Sciences
  • biOasis Technologies
  • Ossianix
  • Angiochem
  • Genervon Biopharmaceuticals
  • NEUWAY Pharma
  • Tranquis Therapeutics
  • CERES BRAIN Therapeutics
  • Nanomerics
  • Reglagene
(Full list of 580+ companies and organizations captured is available in the report)

PowerPoint Presentation (Complimentary)

Available

Customization Scope

15% Free Customization

Excel Data Packs (Complimentary)

  • Blood-Brain Barrier Drugs Market Landscape
  • Blood-Brain Barrier Technology Market Landscape
  • Technology Competitiveness Analysis
  • Partnerships and Collaborations 
  • Recent Licensing Agreements Analysis
  • Funding and Investment Analysis 
  • Patent Analysis
  • Chessboard Strategy Analysis
  • Likely Partner Analysis
  • Market Size and Opportunity Analysis


One of the key objectives of this market report was to estimate the blood-brain barrier market trends, blood brain barrier market size, blood-brain barrier market analysis opportunity and the future growth potential for the blood-brain barrier market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035.

The blood-brain barrier market report also features a detailed analysis and the likely distribution of the current and forecasted opportunity within this market across various segments, such as type of molecule (small molecules and biologics), route of administration (oral, intravenous), target disease indication (multiple sclerosis, mucopolysaccharidosis type ii (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type iii a (sanfilippo syndrome a)), therapeutic area (neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Small Company, US
  • Chief Executive Officer and Founder, Small Company, UK
  • Chief Executive Officer and Co-Founder, Very Small Company, the Netherlands
  • Chief Executive Officer, Small Company, US
  • Chief Executive Officer, Very Small Company, US 
  • Chief Operating Officer, Mid-sized  Company, Switzerland
  • Chief Operating Officer, Small Company ,Spain
  • Head of Clinical Affairs, Very Small Company, France
  • Head of Drug Development, Small Company, France
  • Professor, US -based Research Institute

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Blood Brain Barrier Market Segmentation Overview

Market Share by Type of Molecule

The blood-brain barrier market is segmented into small molecules and biologics, based on the type of molecule. Currently, the biologics market segment captures maximum share (100%) of the overall market; however, the market for small molecules is likely to grow at a relatively faster pace (CAGR of 31.9%) in the next decade. The anticipated shift is driven by advancements in small molecule technologies, offering improved penetration and efficacy in crossing the blood-brain barrier compared to biologics.

Additionally, small molecules often present advantages in terms of manufacturing scalability, cost-effectiveness, and potential for oral administration, making them increasingly attractive for neurological therapies. As research continues to enhance the understanding and development of small molecule-based treatments, they are poised to become the primary choice for blood-brain barrier targeting strategies.

Market Share by Route of Administration

Based on the route of administration, the blood-brain barrier market is segmented into oral and intravenous. Currently, the intravenous route of administration market segment captures the maximum market share (100%) of the overall market; however, the market for oral route of administration is expected to witness substantial growth (CAGR 31.9%) in the next decade. The anticipated shift is driven by various factors such as patient preference, advancements in drug delivery technologies, increased R&D efforts, reduced risk of complications, and rising demand for effective treatments for neurological disorders.

Market Share by Target Disease Indication

The blood-brain barrier market is segmented into multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A), based on the target disease indication. Currently, the blood brain barrier drugs offering treatment for hunter syndrome captures 100% share of the overall market; however, the blood brain barrier drugs offering treatment for multiple sclerosis is likely to grow at a relatively faster pace (CAGR 29.2%) in the next decade.

The increasing prevalence of multiple sclerosis and the need for more effective treatments are driving the demand for these therapies. Further, therapies intended for the treatment of mucopolysaccharidosis type III A (sanfilippo syndrome A ) are also likely to grow at a rapid pace in the future, owing to the fact that currently there is no approved branded therapies / medication for the treatment of Sanfilippo Syndrome A.

Market Share by Therapeutic Area

Based on the therapeutic area, the blood-brain barrier market is segmented into neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders. Currently the lysosomal storage disorders market segment dominates the overall market; however, the market for neurodegenerative disorders is expected to witness substantial growth (CAGR 31.9%) in the next decade. The anticipated shift is driven by increasing incidence of neurodegenerative disorders, with over million people living with the indication worldwide.  Further, the currently available drugs are not very effective in treating the root cause of this indication. However, once the blood-brain barrier penetrating drugs enter into the market, the prevalence rate of this indication is likely to fall.

Market Share by Key Geographical Regions

The blood-brain barrier market is segmented into North America, Europe, Asia-Pacific, and Rest of the World, based on the key geographical regions. Currently, Asia-Pacific and Rest of the World captures maximum share (100%) of the overall market; however, blood-brain barrier market in North America is likely to grow at a relatively faster pace (a CAGR 29%) in in the next decade. The anticipated shift is driven by numerous factors that contribute to the region’s dominance in this industry, including the presence of several well-established drug developers with extensive manufacturing capabilities in the North America. Additionally, the advanced healthcare infrastructure and research capabilities in North America enable drug developers to conduct extensive clinical trials required to meet the stringent regulatory guidelines of the drug approval bodies.

Digital Biomarkers Market Key Insights

The “Blood-Brain Barrier Market (3rd Edition), Industry Trends and Global Forecasts, till 2035: Distribution by Type of Molecule (Small Molecules and Biologics), Route of Administration (Oral and Intravenous), Target Disease Indications (Multiple Sclerosis, Mucopolysaccharidosis Type II (Hunter Syndrome), Amyotrophic Lateral Sclerosis, Leptomeningeal Carcinomatosis and Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A), Therapeutic Area (Neurodegenerative Disorders, Lysosomal Storage Disorders and Neuro-Oncology Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)” report features an extensive study of the current market landscape, blood-brain barrier market size and future opportunities associated with blood brain barrier drugs market size, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the blood-brain barrier market report are briefly discussed below.

Competitive Landscape of Blood-Brain Barrier Therapies

The market landscape of blood-brain barrier therapies is dynamic and diverse, with close to 130 blood-brain barrier therapies either approved or currently being evaluated in different stages of development. It is important to note that till date only one therapy has been approved for the treatment of mucopolysaccharidosis type II (hunter syndrome), and majority of the drug candidates are currently in preclinical stage of development. Further, blood-brain barrier therapies can be administered through various routes of administration, such as oral, intravenous, intranasal, subcutaneous and transmucosal; this diversity allows healthcare providers to tailor treatment regimens to individual patient needs, thereby enhancing patient adherence and treatment outcomes. Overall, the market landscape of blood-brain barrier therapies is characterized by innovation, competition, and affordability, providing patients with access to high-quality and cost-effective treatment options for a wide range of disease indications.

Competitive Landscape of Blood Brain Barrier Technologies Market

The market landscape of blood-brain barrier technologies comprises of over 30 unique blood-brain barrier penetration technologies that are developed by various industry players across the world. These technologies play a crucial role in the development and manufacturing of blood-brain barrier therapies, contributing to their efficacy, safety, and affordability. Blood brain barrier technologies market encompasses a range of innovations and advancements in drug delivery systems, formulation techniques, manufacturing processes, and quality control methods, ultimately enhancing the overall quality of the therapies.

Market Analysis: Global Blood Brain Barrier Market Size

The global blood-brain barrier market is estimated to be worth USD 36 million in 2024. Further, driven by the increasing incidences of neurological disorders, rising investment activity along with the continuous technological advancements in this domain, the market is anticipated to grow at a CAGR of 49% during the forecast period.

North America is likely to Hold the Largest Share of the Blood-Brain Barrier Market, by 2035

Presently, Asia-Pacific and Rest of the World captures maximum share of the overall market; however, North America is likely to grow at a relatively faster pace in the next decade. The anticipated shift is driven by the growing preference for blood-brain barrier therapies due to favourable regulatory guidelines and early approvals in this region by the FDA. Additionally, the presence of major pharmaceutical companies and research institutions in North America drives innovation and facilitates the introduction of blood-brain barrier therapies to the market. The advanced healthcare infrastructure and research capabilities in North America enable drug developers to conduct extensive clinical trials required to meet the stringent regulatory guidelines of the drug approval bodies.

Key Players in the Blood-Brain Barrier Market

Examples of key players (which have also been profiled in this report) involved in blood-brain barrier domain includes (in alphabetical order) Angiochem, biOasis Technologies, CERES BRAIN Therapeutics, Cyclenium Pharma, Denali Therapeutics, Genervon Biopharmaceuticals, ICBI, JCR Pharmaceuticals, Lauren Sciences, Nanomerics, NEUWAY Pharma, Ossianix, Reglagene and Tranquis Therapeutics.

Blood-Brain Barrier Market Report Coverage

The blood-brain barrier market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:

  • An outline of the systematic research methodology adopted to conduct the study on blood-brain barrier industry, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
Blood Brain Barrier Market, List of Therapies and Technologies Blood Brain Barrier Market, Competitiveness Analysis Blood Brain Barrier Market, Licensing Agreements

 

  • An overview of economic factors that impact the overall blood-brain barrier market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of blood-brain barrier market and its likely evolution in the mid-long term.
  • A general introduction of the blood-brain barrier, featuring insights on the growing burden of neurological disorders, strategies for drug delivery to the CNS and invasive technique. It provides a brief introduction to non-invasive techniques / approaches. Additionally, the chapter includes details on the various strategies for drug delivery across the blood-brain barrier. Further, the chapter highlights the challenges associated with blood-brain barrier penetration and CNS drug delivery.
  • A general overview of important concepts related to the structure of human brain, its components and their functions in the central nervous system (CNS). It also presents an elaborate discussion on the different invasive and non-invasive strategies used to deliver drugs into the CNS. Further, the chapter provides an overview of the concept of blood-brain barrier, historical evolution, including its role for efficient drug delivery and growing burden of neurological disorders. Furthermore, it provides information on the popular concepts used to develop BBB permeable drugs and technologies or to bypass the barrier. The chapter also includes a discussion on the key challenges associated with the use of BBB penetration technologies for efficient drug delivery to CNS.
  • An overview of the current market landscape of blood-brain barrier penetration technologies along with information on several relevant parameters, such as such as status of development (commercialized and under development), technology principle (drug delivery methods, biological approaches, physical techniques and others / unspecified), type of compatible pharmacological molecule crossing the blood-brain barrier (biologics, small molecule, oligonucleotides and others), target disease indication, type of patent, and licensing activity. This includes information on the technology developers, along with their year of establishment, company size (in terms of number of employees) and geographical location.
  • An overview of the current market landscape of blood-brain barrier penetrating therapies that are approved or currently being evaluated in clinical trials, featuring a detailed analysis based on relevant parameters, such as stage of development (approved, phase III, phase II, phase I, IND-enabling, pre-clinical and discovery), type of molecule (biologics, small molecules and other molecules), affiliated BBB penetration, route of administration (intranasal, intravenous, oral, subcutaneous and transmucosal) target disease indication and therapeutic area (neurodegenerative disorders, lysosomal storage disorders, neuro oncology disorders, oncological disorders, infectious diseases, pain disorders, autoimmune disorders, CNS disorders, cerebrovascular disorders and others). Additionally, the chapter includes an overview on the landscape of BBB penetrating therapy developers, presenting a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on employee count), location of headquarters and most active players (in terms of the number of therapies).
  • Elaborate profiles of prominent technology developers engaged (shortlisted based on the following criteria: companies having more than three drugs (being developed using proprietary BBB technologies) in preclinical / clinical phase of development) in this domain, featuring an overview of the company, technology portfolio, product portfolio and recent developments and future outlook.
  • An insightful company competitiveness analysis of the blood-brain barrier technologies captured in our database, taking into consideration relevant parameters, such as developer strength (in terms of years of experience, company size and status of development), technology strength (in terms of type of compatible pharmacological molecule crossing the BBB, availability of patent protection, number of collaborations number of drugs developed and highest phase of development). 
  • A general overview on the working principle of the most common approaches being utilized for the development of blood-brain barrier penetration technologies, such as RMT (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the blood-brain barrier, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).
  • A detailed analysis of the partnerships inked between stakeholders in the blood-brain barrier industry, based on several parameters, such as year of partnership, type of partnership, type of compatible pharmacological molecule, therapeutic area, type of partner and most active players (in terms of the number of partnerships signed) and regional distribution of partnership activity that have taken place in this domain, during the period pre-2018-2024 (till March).
  • A detailed discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders. This chapter features a detailed analysis based on relevant parameters, such as year of agreement, type of licensing agreement, most active players (in terms of number of licensing agreements), most popular technologies (in terms of number of licensing agreements) and geography.
  • An analysis of the funding and investments that have been made into companies developing blood-brain barrier penetration technologies and drugs, which include venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place during the period 2020 to 2024 (till march), highlighting the growing interest of venture capital (VC) community and other strategic investors in this market.
Blood Brain Barrier Market, Funding and Investments Blood Brain Barrier Market, Likely Partner Analysis Blood Brain Barrier Market, Likely Growth Scenarios

 

  • An in-depth analysis of various patents that have been filed / granted related to blood-brain barrier, since 2018, taking into consideration parameters, such as patent publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers with clinical candidates engaged in this domain. The analysis was designed to enable stakeholder companies to improve their existing drug development strategies in order to accelerate the progress of their lead drug candidates.
  • An insightful 3D bubble chart highlighting the market potential of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), based on the number of already approved drugs, number of pipeline drugs and the target patient population. It also includes an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each respective indication.
  • A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with blood-brain barrier penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), target indication, type of molecule, route of administration and  mechanism of action.
  • An in-depth analysis of the factors that can impact the growth of blood-brain barrier market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed market forecast analysis in order to estimate the existing market size and future opportunity for global blood-brain barrier penetrating therapies market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the global blood-brain barrier penetrating therapies market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across different types of molecules, such as small molecules and biologics.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across various routes of administration, such as oral and intravenous.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across different target disease indications, such as multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A).
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across various therapeutic areas, such as neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across various key geographical regions, such as North America, Europe and Asia-Pacific and Rest of the World.
  • Details pertaining to the sales forecast for approved / phase III drugs in the BBB penetrating therapies market.
Blood Brain Barrier Market, Distribution by Key Geographical Regions Blood Brain Barrier Market, Movement Analysis Blood Brain Barrier Market, Penetration Growth Matrix


Recent Developments in Blood Brain Barrier Market

Several recent developments have taken place in the field of blood brain barrier market, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.

  • In February 2024, Denali Therapeutics raised USD 500 million through a private placement, aiming to advance research, development, and its BBB-crossing Transport Vehicle technology for neurodegenerative diseases.
  • In February 2024, Attralus, has raised USD 56 million through Venture Capital (Series B+) round to advance its research and development of therapeutics for rare diseases.
  • In January 2024, Vect-Horus signed an exclusive licensing agreement with Ionis Pharmaceuticals for target selection using  Vect-Horus’ platform technology VECTrans for systemic delivery of RNA-targeted therapeutics.
  • In December 2023, JCR Pharmaceuticals has signed a research and development agreement with Alexion to develop innovative oligonucleotide therapeutics using JCR's proprietary J-Brain Cargo technology for targeted delivery to certain tissues or organs in rare diseases.

Authors: Simran Kaur, Tamanna Sharma and Hardik Patel

Frequently Asked Questions

Question 1: What is the blood-brain barrier?

Answer: The blood brain barrier (BBB) is a highly selective semipermeable membrane that separates the circulating blood from the brain's extracellular fluid. It is formed by specialized endothelial cells lining the capillaries of the brain, along with astrocytes and pericytes. The BBB plays a crucial role in protecting the brain by regulating the passage of substances, such as ions, molecules, and cells, between the bloodstream and the brain tissue. It helps maintain the brain's microenvironment by preventing harmful substances from entering while allowing essential nutrients and molecules to pass through. The blood-brain barrier also serves as a barrier to many drugs, limiting their ability to effectively treat neurological disorders.

Question 2: How big is the blood-brain barrier market?

Answer: The blood brain barrier market size is anticipated to be worth USD 36 million in 2024 and is expected to grow at a CAGR of 49% during the forecast period 2024 to 2035.

Question 3: Which are the top players in blood-brain barrier market?

Answer: The top players included in the blood-brain barrier market are Angiochem, biOasis Technologies, CERES BRAIN Therapeutics, Cyclenium Pharma, Denali Therapeutics, Genervon Biopharmaceuticals, ICBI, JCR Pharmaceuticals, Lauren Sciences, Nanomerics, NEUWAY Pharma, Ossianix, Reglagene and Tranquis Therapeutics.

Question 4: What are the factors driving the blood-brain barrier market?

Answer: The factors driving the blood-brain barrier market include rising prevalence of neurological disorders and ongoing technological advancements.

Question 5: Which region has the highest market share in blood-brain barrier market?

Answer: Currently, Asia-Pacific and Rest of the World holds 100% of the market share.

Question 6: What are the leading market segments in blood-brain barrier market?

Answer: Currently, in terms of type of molecule market segment, biologics captures the largest blood-brain barrier market share.

Question 7: What is the likely market size for blood-brain barrier penetrating therapies market?

Answer: The blood-brain barrier penetrating therapies market size is anticipated to be worth USD 36 million in 2024, and this value is projected to reach USD 2,904 million by 2035.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com